r-STRAT-PRO: Risk STRATification of PROstate cancer patients using novel rapid Leukocyte ImmunoTest™ blood test

r-STRAT-PRO：使用新型快速白细胞免疫测试™ 血液检测对前列腺癌患者进行风险分层

• 批准号: 104576
• 金额: $ 8.82万
• 依托单位: OXFORD MEDISTRESS LTD
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=104576
• 关键词: STRAT; PRO; Risk; STRATification; PROstate

"Prostate cancer is the most common cancer in European males, with over 340,000 new cases and 71,000 deaths each year in the EU. Indeed, experts predict up to 1 in 8 men in the EU will be diagnosed with prostate cancer during their lifetime. Significant progress has been made in recent years in detecting the onset of prostate cancer. In particular, prostate-specific antigen (PSA) from blood tests has been found to be a useful marker of prostate disease; however, a number of studies have shown that it often results in ""false positives"" that can lead to worry and anxiety among patients. Therefore, a need exists for new tools to rapidly classify patients based on likely disease severity, to monitor disease progression and to enable the development of home monitoring kits for monitoring disease progression and recurrence.To address this unmet clinical need, Oxford MediStress (OMS) has developed the Leukocyte ImmunoTest(tm) (LIT(tm)) for rapidly assessing neutrophil function, a key aspect of the immune system. The rapid, portable, hand-held point-of-care (POC) test analyses a pinprick of blood and quantitatively evaluates how well an individual's white blood cells (their so-called ""neutrophils"") are capable of responding to chemical ""stimulation"" in a test tube when mixed with our patented chemicals. The test has been successfully evaluated recently in a clinical trial involving prostate cancer patients in London to see if the ten-minute test could pick out which patients had the most severe disease. According to our collaborating cancer experts, these results provide confidence the test could one day act as a risk stratification method and as a method to monitor disease progression in prostate and other cancers, including breast cancer.The outputs of the proposed feasibility study will increase our understanding of how the test can be used in current clinical practice for risk stratification and disease monitoring in prostate cancer and to see whether it could be used in other areas of prostate cancer monitoring, as well as in other cancers. Finally, the project will improve our understanding of the clinical-regulatory and manufacturing strategies that the Company will need to adopt to be successful and, at the same time, benefit the patient and healthcare-provider."

“前列腺癌是欧洲男性最常见的癌症，欧盟每年有超过340,000例新病例和71,000例死亡。的确，专家预测，欧盟中有大量八分之一的男性将在其一生中被诊断出患有前列腺癌。近年来，在检测前列腺癌的发作方面取得了进展。通常会导致“误报”，从而导致患者的忧虑和焦虑，因此需要根据可能的疾病严重程度快速对患者进行分类，以监测疾病进展并实现家庭监测套件的发展。为了监测疾病的进展和复发。为了满足这种未满足的临床需求，牛津大麻（OMS）开发了白细胞免疫脱发（TM）（LIT（TM）），用于快速评估中性粒细胞功能，这是免疫系统的关键方面。快速，便携式，手持式护理点（POC）测试分析了血液的针刺，并定量评估了一个人的白血细胞（其所谓的“中性粒细胞”）能够对化学响应的响应”。与我们的专利化学物质混合时，在试管中“刺激”。该测试最近在一项涉及伦敦前列腺癌患者的临床试验中成功评估了该测试，以查看10分钟的测试是否可以挑出哪些患者患有最严重的疾病。根据我们合作的癌症专家的说法，这些结果提供了信心。测试有一天可以作为一种风险分层方法，并作为监测前列腺癌和其他癌症（包括乳腺癌）的疾病进展的方法。拟议的可行性研究的输出将增加我们了解该测试如何在当前的临床实践中用于前列腺癌中的风险分层和疾病监测，并查看是否可以在前列腺癌监测的其他领域以及其他癌症中使用。最后，该项目将提高我们对公司将需要采用的临床调控和制造策略的理解，并同时使患者和医疗保健提供者受益。”